ArticleMolecular pharmaceutics2014
Aptamer-targeted DNA nanostructures for therapeutic delivery.
Article in Molecular pharmaceutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 135 citations in OpenAlex.
- Dynamic PET Imaging of EpCAM-Positive Colorectal Cancer Using Radiolabeled DTN-SYL3C Aptamer Conjugates.ACS omega · 2025Article
- Article
- Review
- Precision Oncology: Advances in Drug Delivery and Imaging.Recent advances in drug delivery and formulation · 2025Review
- AI-based Prediction of Protein Corona Composition on DNA Nanostructures.bioRxiv : the preprint server for biology · 2024Article
- Revolutionizing cancer therapy using tetrahedral DNA nanostructures as intelligent drug delivery systems.Nanoscale advances · 2024Review
- Advancements in Aptamer-Driven DNA Nanostructures for Precision Drug Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Cell-Surface Binding of DNA Nanostructures for Enhanced Intracellular and Intranuclear Delivery.ACS applied materials & interfaces · 2024Article
- DNA tetrahedral nanostructures for the biomedical application and spatial orientation of biomolecules.Bioactive materials · 2024Review
- DNA-Based Nanomaterials as Drug Delivery Platforms for Increasing the Effect of Drugs in Tumors.Cancers · 2023Review
- Nucleic acid nanostructures forApplied physics reviews · 2023Review
- RNA-based therapeutics: an overview and prospectus.Cell death & disease · 2022Review
- Tuning Design Parameters of ICAM-1-Targeted 3DNA Nanocarriers to Optimize Pulmonary Targeting Depending on Drug Type.Pharmaceutics · 2022Article
- Metallointercalators-DNA Tetrahedron Supramolecular Self-Assemblies with Increased Serum Stability.ACS nano · 2022Article
- Therapeutic Applications of Programmable DNA Nanostructures.Micromachines · 2022Review
- DNA Nanodevice-Based Drug Delivery Systems.Biomolecules · 2021Review
- Tetrahedral DNA nanostructures for effective treatment of cancer: advances and prospects.Journal of nanobiotechnology · 2021Review
- Functionalizing DNA nanostructures for therapeutic applications.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2021Review
- AS1411 Aptamer Linked to DNA Nanostructures Diverts Its Traffic Inside Cancer Cells and Improves Its Therapeutic Efficacy.Pharmaceutics · 2021Article
- The biological applications of DNA nanomaterials: current challenges and future directions.Signal transduction and targeted therapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
DNA-based nanostructures have been widely used in various applications due to their structural diversity, programmability, and uniform structures. Their intrinsic biocompatibility and biodegradability further motivates the investigation of DNA-based nanostructures as delivery vehicles. Incorporating AS1411 aptamers into DNA pyramids leads to enhanced intracellular uptake and selectively inhibits the growth of cancer cells, achieved without the use of transfection reagents. Furthermore, aptamer-displaying pyramids are found to be substantially more resistant to nuclease degradation than single-stranded aptamers. These findings, along with their modularity, reinforce the potential of DNA-based nanostructures for therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.